Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-521752-26-00
Authorised, recruiting Phase II

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

2025-521752-26-00 · tracked via the Priya Life Science EU tracker
Sponsor
Adarx Pharmaceuticals Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Male Urogenital Diseases
Decision date
02/03/2026
Enrollment target
7
Sites
Spain, Italy

Condition studied

Complement-Mediated Kidney Disease

Investigational medicinal product(s)

Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valentadsorbed)Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups ACW-135 and Y conjugate vaccineInfanrix hexaPowder and suspension for suspension for injection. Diphtheria (D)tetanus (T)pertussis (acellularcomponent) (Pa)hepatitis B (rDNA) (HBV)poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed).Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNAcomponentADX-038

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Incidence and severity of TEAEs

Endpoint detail

1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521752-26-00 on CTIS ↗ ← All trials in the EU